Full Text View
Tabular View
No Study Results Posted
Related Studies
A Long-Term Safety Study of Once-Daily Travatan
This study is ongoing, but not recruiting participants.
Study NCT00051168   Information provided by Alcon Research
First Received: January 3, 2003   Last Updated: August 4, 2008   History of Changes

January 3, 2003
August 4, 2008
January 2006
April 2009   (final data collection date for primary outcome measure)
 
 
Complete list of historical versions of study NCT00051168 on ClinicalTrials.gov Archive Site
 
 
 
A Long-Term Safety Study of Once-Daily Travatan
A Long-Term Safety Study of Once-Daily TRAVATAN

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

 
Phase III
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Drug: Travoprost (0.004%)
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
 
April 2009
April 2009   (final data collection date for primary outcome measure)

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00051168
 
C-02-20
Alcon Research
 
 
Alcon Research
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP